Sanofi India has received setback during the first quarter ended March 2017 mainly due to lower export volumes and rupee appreciation versus the Euro. Further, its profit also adversely impacted due to price reduction following the fixation of the ceiling prices under DPCO.
Sanofi's net profit declined by 27.4 per cent to Rs.60 crore from Rs.82.6 crore in the corresponding quarter of last year. Its net sales declined by 1.1 per cent to Rs.513 crore from Rs.518 crore. EPS worked out to Rs.26.09 as against Rs.35.91 in the last period.
The company recommended final dividend of Rs.50 per equity share of Rs.10 for the year ended December 31, 2016.
For the full year ended December 2016, Sanofi India registered net sales growth of 7.9 per cent to Rs.2,420 crore as compared to Rs.2,243 crore in the previous year. Its net profit improved marginally by 6.3 per cent to Rs.297 crore from Rs.159 crore. Net revenue from India contributed 73 per cent of net revenue from operations, increased from Rs.1,615 crore in 2015 to Rs.1,729 crore. Its sales outside India contributed to 27 per cent of net revenue from operations and increased to Rs.640 crore from Rs.578 crore. Four products viz. Lantus, Combiflam, Clexane and Allegra feature in the top 100 pharma brands in India.
Sanofi india ne
